Orchestra BioMed Holdings Inc (OBIO)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$5.59+2.19%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Orchestra BioMed Holdings Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	134,429
EPS	—	-0.412
Annual ending 2026-12-31
Revenue	—	454,000
EPS	—	-1.516
Annual ending 2027-12-31
Revenue	—	577,286
EPS	—	-1.506

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
cash proceeds of up to $21 million from Vivasure acquisition	The company recently gained $21 million from an acquisition.	Intact	cash proceeds from acquisition fall materially short of $21 million	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
annual revenue reaches at least $11 million in 2026	It expects revenue of at least $11 million in 2026 and $30 million in 2025.	Intact	annual revenue falls below $11 million in FY26	Revenue: $88,000 FY2026-Q2; GAAP. Published target: >= $11 million. Target period is not explicitly aligned with this observation. Source published Aug 10, 202688,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 60649103-84ac-45ce-b86f-9e0a85cbf0b1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
annual revenue reaches at least $30 million in 2025	It expects revenue of at least $11 million in 2026 and $30 million in 2025.	Broken	annual revenue falls below $30 million in FY25	Revenue: $88,000 FY2026-Q2; GAAP. Published target: >= $30 million. Target period is not explicitly aligned with this observation. Source published Aug 10, 202688,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 60649103-84ac-45ce-b86f-9e0a85cbf0b1. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.51

$-1.45 → $-1.51 · observed estimates

FY2027 revenue$0.00B

$0.00B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.45	$655,429	5 / 6
2026-07-25	$-1.45	$655,429	5 / 6
2026-07-26	$-1.45	$655,429	5 / 6
2026-07-27	$-1.45	$655,429	5 / 6
2026-07-28	$-1.45	$655,429	5 / 6
2026-07-29	$-1.46	$655,430	6 / 7
2026-07-30	$-1.46	$655,430	6 / 7
2026-07-31	$-1.45	$655,429	5 / 6
2026-08-01	$-1.45	$655,429	5 / 6
2026-08-02	$-1.46	$655,430	6 / 7
2026-08-03	$-1.45	$655,429	5 / 6
2026-08-04	$-1.46	$655,430	6 / 7
2026-08-05	$-1.45	$655,429	5 / 6
2026-08-06	$-1.45	$655,429	5 / 6
2026-08-07	$-1.45	$655,429	5 / 6
2026-08-08	$-1.46	$655,430	6 / 7
2026-08-09	$-1.46	$655,430	6 / 7
2026-08-10	$-1.46	$655,430	6 / 7
2026-08-12	$-1.45	$655,429	5 / 6
2026-08-13	$-1.45	$643,570	6 / 7
2026-08-14	$-1.45	$655,429	5 / 6
2026-08-15	$-1.45	$655,429	5 / 6
2026-08-16	$-1.45	$655,429	5 / 6
2026-08-17	$-1.45	$655,429	5 / 6
2026-08-18	$-1.45	$655,429	5 / 6
2026-08-19	$-1.45	$655,429	5 / 6
2026-08-20	$-1.50	$577,286	5 / 6
2026-08-21	$-1.50	$577,286	5 / 6
2026-08-22	$-1.50	$577,286	5 / 6
2026-08-23	$-1.50	$577,286	5 / 6
2026-08-24	$-1.50	$577,286	5 / 6
2026-08-25	$-1.50	$577,286	5 / 6
2026-08-26	$-1.50	$577,286	5 / 6
2026-08-27	$-1.50	$577,286	5 / 6
2026-08-28	$-1.50	$577,286	5 / 6
2026-08-29	$-1.50	$577,286	5 / 6
2026-08-30	$-1.50	$577,286	5 / 6
2026-08-31	$-1.50	$577,286	5 / 6
2026-09-01	$-1.50	$577,286	5 / 6
2026-09-02	$-1.50	$577,286	5 / 6
2026-09-03	$-1.50	$577,286	5 / 6
2026-09-04	$-1.50	$577,286	5 / 6
2026-09-05	$-1.50	$577,286	5 / 5
2026-09-06	$-1.50	$577,286	5 / 5
2026-09-07	$-1.50	$577,286	5 / 5
2026-09-08	$-1.50	$577,286	5 / 5
2026-09-09	$-1.50	$577,286	5 / 5
2026-09-10	$-1.50	$577,286	5 / 5
2026-09-11	$-1.50	$571,571	5 / 5
2026-09-12	$-1.50	$571,571	5 / 5
2026-09-13	$-1.50	$571,571	5 / 5
2026-09-14	$-1.50	$571,571	5 / 5
2026-09-15	$-1.50	$571,571	5 / 5
2026-09-16	$-1.51	$571,571	5 / 5
2026-09-17	$-1.51	$571,571	5 / 5
2026-09-18	$-1.51	$571,571	5 / 5
2026-09-19	$-1.51	$571,571	5 / 6
2026-09-20	$-1.51	$571,571	5 / 6
2026-09-21	$-1.51	$571,571	5 / 6
2026-09-22	$-1.51	$571,571	5 / 6
2026-09-23	$-1.51	$571,571	5 / 6
2026-09-24	$-1.51	$571,571	5 / 6
2026-09-25	$-1.51	$571,571	5 / 6
2026-09-26	$-1.51	$571,571	5 / 6
2026-09-27	$-1.51	$571,571	5 / 6
2026-09-28	$-1.51	$571,571	5 / 6
2026-09-29	$-1.51	$571,571	5 / 6
2026-09-30	$-1.51	$571,571	5 / 6
2026-10-01	$-1.51	$571,571	5 / 6
2026-10-02	$-1.51	$571,571	5 / 6
2026-10-03	$-1.51	$577,286	5 / 6
2026-10-04	$-1.51	$577,286	5 / 6
2026-10-05	$-1.51	$577,286	5 / 6
2026-10-06	$-1.51	$577,286	5 / 6
2026-10-07	$-1.51	$577,286	5 / 6
2026-10-08	$-1.51	$577,286	5 / 6
2026-10-09	$-1.51	$577,286	5 / 6
2026-10-10	$-1.51	$577,286	5 / 6
2026-10-11	$-1.51	$577,286	5 / 6
2026-10-12	$-1.51	$577,286	5 / 6
2026-10-13	$-1.51	$583,000	5 / 6
2026-10-14	$-1.51	$577,286	5 / 6
2026-10-15	$-1.51	$577,286	5 / 6
2026-10-16	$-1.51	$577,286	5 / 6
2026-10-17	$-1.51	$577,286	5 / 6
2026-10-18	$-1.51	$577,286	5 / 6
2026-10-19	$-1.51	$577,286	5 / 6
2026-10-20	$-1.51	$577,286	5 / 6
2026-10-21	$-1.51	$577,286	5 / 6
2026-10-22	$-1.51	$577,286	5 / 6
2026-10-23	$-1.51	$577,286	5 / 6
2026-10-24	$-1.51	$577,286	5 / 6

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	7	1
2026-06-01	6	1
2026-07-01	6	1
2026-08-01	6	1
2026-09-01	7	1
2026-10-01	7	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 7 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades1 maintains

Recent actions · Sep 25–Oct 24 · 1 recorded

Price-target changes

30 days

○ Previous · ● Latest · common dollar scale

H.C. WainwrightOct 5

$10.00New observation · no comparable prior

$0$5.50$11.00

0 raises · 0 cuts · 0 unchanged · 1 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

cash proceeds of up to $21 million from Vivasure acquisitionDirect metric needs a verified mapping
annual revenue reaches at least $11 million in 2026Revenue: $88,000
annual revenue reaches at least $30 million in 2025Published status: Broken

Next proof point

Nov 9, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-34.8%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Orchestra BioMed Holdings Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-development business, not an established earnings compounder. The multi-year view is intact, with pivotal-trial enrollment on track, but the recent signal has shifted from mixed to cautious.

What's priced into Orchestra BioMed Holdings Inc

The valuation model points to a premium versus peers, with an expectations gap that suggests meaningful expectations are already embedded. That reading has low confidence, and no valuation fragility gates have fired.

What the fundamentals likely do

Near term, earnings remain loss-making and erratic, with elevated risk of a disappointing report. Over the multi-year view, completing enrollment in the BACKBEAT trial ahead of its target supports progress toward primary endpoint data expected in Q2 2027; partner funding and milestone proceeds also support development, though revenue progress remains a watch item.

What Orchestra BioMed Holdings Inc hinges on

The thesis depends on OBIO meeting trial and regulatory milestones and sustaining support from partners including Medtronic, Terumo, and Ligand. A guidance cut or further weakening in jobs data could pressure the business outlook, while strong earnings and guidance from healthcare peers could support sector momentum.